Results 151 to 160 of about 3,918,910 (289)

CONTEST: A generalization of ONEST to estimate sample size for predictive augmented intelligence method validation studies. [PDF]

J Pathol Inform
Olson BK, Rosenthal JH, Kappedal RD, Olson NH.   +3 more
europepmc   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

In Vitro Calcification of Bioprosthetic Heart Valves: Method Validation by Comparative Heart Valve Calcification Testing. [PDF]

Artif Organs
Kiesendahl N, Schmitz C, Peters L, Weiler M, Schmitz-Rode T, Steinseifer U, Clauser JC.   +6 more
europepmc   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

Baicalin nano-micelles for dry eye disease: LC-MS/MS method validation, pharmacokinetics and pharmacodynamics in preclinical models. [PDF]

Saudi Pharm J
Wang Z, Xu Y, Liu M, Yang Y, Shi W, Zhu Q, Liu J, Yi L, Wu H, Yin X, Dong X, Ni J, Qu C.   +12 more
europepmc   +1 more source

Method Validation for Multi-Pesticide Residue Determination in Chrysanthemum. [PDF]

Molecules, 2023
Wang X, Wang Z, Yu J, Wu L, Zhang X, Luo F, Chen Z, Zhou L.   +7 more
europepmc   +1 more source

Somatic mutational landscape in von Hippel–Lindau familial hemangioblastoma

Molecular Oncology, EarlyView.
The causes of central nervous system (CNS) hemangioblastoma in Von Hippel–Lindau (vHL) disease are unclear. We used Whole Exome Sequencing (WES) on familial hemangioblastoma to investigate events that underlie tumor development. Our findings suggest that VHL loss creates a permissive environment for tumor formation, while additional alterations ...
Maja Dembic, Anne Nørremølle, Lilian Bomme Ousager, Lars van Brakel Andersen, Marie Louise Mølgaard Binderup, Mads Thomassen   +5 more
wiley   +1 more source

Method validation and assessment of the biodistribution and shedding for adenovirus vector-based vaccine using qPCR and dPCR. [PDF]

Mol Ther Methods Clin Dev
Tanaka Y, Hamano S, Ishii-Watabe A, Saito Y, Kikura-Hanajiri R.   +4 more
europepmc   +1 more source

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Molecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou   +4 more
wiley   +1 more source

Phytochemical Characterization of <i>Pouteria guianensis</i>: Optimized Flavonoid Extraction and HPLC Method Validation. [PDF]

ACS Omega
de Matos RC, Bitencourt AFA, de Oliveira ADM, Moreira CPS, Machado RR, Scopel M.   +5 more
europepmc   +1 more source